- Conditions
- Breast Cancer
- Interventions
- Letrozole, Palbociclib, Goserelin, Oncotype DX Breast Recurrence Score
- Drug · Diagnostic Test
- Lead sponsor
- NSABP Foundation Inc
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 11
- States / cities
- Fountain Valley, California • Laguna Hills, California • Long Beach, California + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 133
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Low Grade Serous Ovarian Cancer
- Interventions
- avutometinib, Defactinib, Pegylated liposomal doxorubicin, Paclitaxel, Letrozole, Anastrozole
- Drug
- Lead sponsor
- Verastem, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 38
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 34 more
- Conditions
- Hormone-Sensitive Breast Cancer, Breast Cancer
- Interventions
- Letrozole, Bevacizumab
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Advanced Breast Cancer
- Interventions
- Lerociclib + Letrozole or Fulvestrant
- Drug
- Lead sponsor
- EQRx, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 6
- States / cities
- Jacksonville, Florida • Omaha, Nebraska • Salem, Oregon + 3 more
- Conditions
- Hepatopulmonary Syndrome
- Interventions
- Letrozole, Placebo
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Breast Cancer
- Interventions
- letrozole, Placebo
- Drug · Other
- Lead sponsor
- NCIC Clinical Trials Group
- Network
- Eligibility
- Up to 120 Years · Female only
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2009
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
- Interventions
- Giredestrant, Giredestrant-matched Placebo, Letrozole, Letrozole-matched Placebo, Palbociclib, LHRH Agonist
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 992 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 37
- States / cities
- Fountain Valley, California • Long Beach, California • San Leandro, California + 32 more
- Conditions
- Lymphangioleiomyomatosis
- Interventions
- Letrozole, Placebo
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 9
- States / cities
- Stanford, California • Jacksonville, Florida • Miami, Florida + 6 more
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Interventions
- Letrozole
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Early Breast Cancer
- Interventions
- Ribociclib, Endocrine Therapy (ET)
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 5,101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2030
- U.S. locations
- 73
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Jonesboro, Arkansas + 68 more
- Conditions
- Breast Cancer, HER2-positive Breast Cancer, ER Positive Breast Cancer, PR-Positive Breast Cancer
- Interventions
- Neratinib, Letrozole (L) or Anastrozole (A), Trastuzumab
- Drug
- Lead sponsor
- Ruth O'Regan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Rochester, New York • Hershey, Pennsylvania + 1 more
- Conditions
- Breast Cancer
- Interventions
- TOL2506, Tamoxifen, Letrozole Tablets, Anastrozole Tablets, Exemestane Tablets
- Drug
- Lead sponsor
- Tolmar Inc.
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 17
- States / cities
- Greenbrae, California • Parker, Colorado • Chicago, Illinois + 14 more
- Conditions
- Breast Cancer
- Interventions
- Gedatolisib, Palbociclib, Letrozole, Fulvestrant
- Drug
- Lead sponsor
- Celcuity Inc
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Corona, California • Fountain Valley, California + 17 more
- Conditions
- Endometrial Cancer
- Interventions
- Letrozole, RAD001 (Everolimus)
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2028
- U.S. locations
- 2
- States / cities
- Morristown, New Jersey • Houston, Texas
- Conditions
- Early Breast Cancer
- Interventions
- Ribociclib, Letrozole, Ansastrozole, Goserelin, Leuprolide, Exemestane
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 1,400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 85
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 74 more
- Conditions
- Breast Cancer
- Interventions
- High Dose Vitamin D, Placebo, Standard Dose Vitamin D3, Letrozole 2.5mg
- Dietary Supplement · Drug
- Lead sponsor
- Qamar Khan
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 2
- States / cities
- Westwood, Kansas • Wichita, Kansas
- Conditions
- Breast Cancer, Hormone Receptor Positive Tumor
- Interventions
- Durvalumab, Anastrozole 1mg, Letrozole 2.5mg, Exemestane 25 MG
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Healthy, no Evidence of Disease, Lobular Breast Carcinoma in Situ
- Interventions
- letrozole, quality-of-life assessment, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 35 Years and older · Female only
- Enrollment
- 112 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2010
- U.S. locations
- 3
- States / cities
- Tucson, Arizona • Rochester, Minnesota
- Conditions
- Breast Cancer
- Interventions
- DPX-Survivac, Letrozole 2.5mg, Cyclophosphamide 50mg, XRT 10Gy x2
- Biological · Drug · Radiation
- Lead sponsor
- Providence Health & Services
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Low Grade Serous Carcinoma
- Interventions
- Ribociclib, Letrozole
- Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 27
- States / cities
- San Francisco, California • Gainesville, Florida • Tampa, Florida + 19 more
- Conditions
- Pregnancy, Polycystic Ovary Syndrome
- Interventions
- Clomiphene citrate, Letrozole
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Stanford, California • Aurora, Colorado + 9 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- Letrozole, Trastuzumab
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2005
- U.S. locations
- 4
- States / cities
- Washington D.C., District of Columbia • Boston, Massachusetts • St Louis, Missouri + 1 more
- Conditions
- Breast Cancer
- Interventions
- Letrozole, Placebo, Taselisib
- Drug · Other
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 334 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 8
- States / cities
- Santa Ana, California • Boston, Massachusetts • Basking Ridge, New Jersey + 5 more
- Conditions
- Breast Neoplasms, Osteoporosis
- Interventions
- Zoledronic Acid, Letrozole
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years · Female only
- Enrollment
- 602 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2009
- U.S. locations
- 43
- States / cities
- Springdale, Arkansas • Burbank, California • Lafayette, California + 39 more